CHMP approves 13 new drugs

13 new treatments have received a positive opinion from the CHMP’s February monthly meeting, while seven drugs have been approved in new indications.

The European Medicines Agency's headquarters in Amsterdam | Photo: Rob Acket/EMA

The European Medicines Agency’s (EMA) expert committee, the CHMP, has given a positive opinion for 13 news drugs, following the committee’s February monthly meeting. This brings the year’s total up to 20 new drugs pending official approval, while 17 existing drugs can await indication expansions.

The Committee for Medicinal Products for Human Use has first given a positive opinion to Immunocore Ireland’s drug Kimmtrak (tebentafusp), a treatment for the rare eye cancer type known as uveal melanoma. This is a difficult to treat condition, as it spreads quickly and has proven resistent to existing treatments, and the drug was therefore reviewed under the CHMP’s accelerated assessment program.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs